Surface-stabilized lopinavir nanoparticles enhance oral bioavailability without coadministration of ritonavir

Nanomedicine (Lond). 2013 Oct;8(10):1639-55. doi: 10.2217/nnm.12.181. Epub 2013 Jan 25.

Abstract

Aim: The aim of the present study was to prepare surface-stabilized nanoparticles (NPs) for oral bioavailability enhancement of lopinavir (LPN), a Biopharmaceutics Classification System class II antiretroviral drug that possesses low oral bioavailability due to its poor aqueous solubility and extensive metabolism by liver microsomal enzymes.

Materials & methods: Surfactant-stabilized LPN-NPs were prepared by combination of antisolvent precipitation and high-pressure homogenization techniques using polyvinyl alcohol as a suitable stabilizer. LPN-NPs were freeze dried by a universal stepwise freeze-drying cycle using mannitol as the cryoprotectant. Pharmacokinetics after oral administration of LPN-NPs were evaluated in male Sprague-Dawley rats and were compared with free LPN coadministered with ritonavir (conventional formulation).

Results & conclusion: Freeze-dried stabilized LPN-NPs possessed particle sizes of approximately 320 nm and a narrow particle size distribution (polydispersity index <0.2). The surface-stabilized LPN-NPs (without ritonavir) demonstrated a 3.11-fold enhancement in bioavailability in comparison to free LPN with ritonavir (conventional formulation).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Animals
  • Anti-Retroviral Agents / administration & dosage*
  • Anti-Retroviral Agents / chemistry
  • Biological Availability
  • Lopinavir / administration & dosage*
  • Lopinavir / chemistry
  • Nanoparticles / administration & dosage*
  • Nanoparticles / chemistry
  • Rats
  • Ritonavir / administration & dosage
  • Surface Properties

Substances

  • Anti-Retroviral Agents
  • Lopinavir
  • Ritonavir